Stuttgart - Delayed Quote EUR

Oryzon Genomics S.A. (ORN.SG)

2.6950

+0.0150

+(0.56%)

At close: April 22 at 8:09:02 AM GMT+2

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

New “Decision to grant” communications in Europe and JapanMADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that the European Patent Office has issued a “Decision to grant” communication for its European patent application EP20712563.4 relating to vafidemstat. The patent, titled “Methods of treating Attention Deficit Hyperactivity Di

GlobeNewswire yesterday

ORYZF
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

In combination with atezolizumab or durvalumabStudy conducted under the CRADA agreement between NCI and Oryzon MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in

GlobeNewswire 7 days ago

ORYZF
High Growth Tech Stocks In Europe March 2025

In March 2025, the European market is navigating a complex landscape characterized by concerns over U.S. trade tariffs, economic growth uncertainties, and fluctuating monetary policies. Despite these challenges, high growth tech stocks in Europe continue to attract attention as investors seek opportunities that align with resilient business models and innovative capabilities capable of weathering broader market volatility.

Simply Wall St. last month

ERIC

ERIXF

ORYZF
European Growth Companies With High Insider Ownership To Watch

As European markets navigate the complexities of U.S. trade tariffs and shifting monetary policies, the pan-European STOXX Europe 600 Index recently experienced a decline amid these uncertainties. In this environment, growth companies with high insider ownership can be particularly interesting to watch, as their leadership's vested interest may align with shareholder value creation during turbulent times.

Simply Wall St. last month

ORYZF

IXX.DE

ATT.ST
ORYZON to Provide Corporate Progress Updates at Several Events in March-April

BIO-Europe Spring 2025Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in March-April. Oryzon will attend the Bio-Europe Spring 2025, whic

GlobeNewswire last month

ORYZF
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat

A non-interventional study published in Frontiers in PsychiatryPsychometric profile characterization of 30 subjects with Phelan-McDermid Syndrome (PMS), defining three distinct subsetsStudy provides clinical scales and thresholds for patient selection in future clinical trials, based on aggressiveness, cognition, and behavioral traitsConducted in collaboration with the Medical and Molecular Genetics Institute (INGEMM) and the Research Institute La Paz Hospital (IdiPaz) in Madrid MADRID and CAMBR

GlobeNewswire last month

ORYZF
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and key secondary endpoints for Phase III trial, aligned with FDA standardsOryzon moves forward with plans to submit Phase III protocol to the FDA in 1H 2025 MADRID and CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmace

GlobeNewswire last month

ORYZF
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced the results of voting at the Extraordinary General Shareholders' Meeting held today in Madrid. A total of 24,030,812 of the Company's issued and outstanding ordinary shares (representing 36.5312% of the share cap

GlobeNewswire last month

ORYZF
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreachPreparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline Personality Disorder ongoing Final data from REIMAGINE proof-of-concept Phase IIa trial published in Psychiatry and Clinical NeurosciencesContinues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophreniaFirst patients dosed in Investigator-initiated Phase I study of

GlobeNewswire last month

ORYZF
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences

The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD) and autistic spectrum disorder (ASD) Vafidemstat demonstrated a relevant clinical benefit in reducing agitation/aggression across all studied patient populations Data was seminal to start further clinical development in BPDAfter an informative Phase IIb in BPD and FDA EoPII meeting, preparation

GlobeNewswire 2 months ago

ORYZF
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board of Directors at the upcoming Shareholders' Meeting, scheduled for February 28. Four new memb

GlobeNewswire 2 months ago

ORYZF
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in an investigator-initiated Phase I dose-finding trial of iadademstat, Oryzon’s potent and selective LSD1 inhibit

GlobeNewswire 2 months ago

ORYZF
ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

MADRID, Spain and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, is pleased to announce the appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor. Dr. Beaurang has over 25 years of experience in biotechnology focusing on corporate strategy, business development, oncology, immunology

GlobeNewswire 2 months ago

ORYZF
ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

Study conducted under the CRADA agreement between NCI and Oryzon MADRID, Spain and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a Phase I dose-finding clinical trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with ven

GlobeNewswire 3 months ago

ORYZF
ORYZON to Provide Corporate Progress Updates at Several Events in January-February

8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum 2025MidCap Events Frankfurt 2025Bio-Neuroscience 2025 MADRID and CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate p

GlobeNewswire 3 months ago

ORYZF
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

Final data from PORTICO, global Phase IIb vafidemstat trial in BPD, presented at the 37th ECNP annual conference in SeptemberCompany moving forward with PORTICO-2 Phase III trial preparations following positive feedback from End-of-Phase II meeting with the FDA Company continues to strengthen IP position for vafidemstat with additional “intention to grant” communications First cohort dosed in Investigator-initiated Phase Ib study of iadademstat with venetoclax and azacitidine in first-line AMLRe

GlobeNewswire 5 months ago

ORYZF
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

FDA’s feedback supports the initiation of the Phase III trialAgitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indicationOryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2Currently no FDA-approved treatments for BPD Company to host conference call and live webcast today at 09:00 am EDT (15:00 pm CET) MADRID and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a

GlobeNewswire 6 months ago

ORYZF
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

Strong improvement in State-Trait Anger Expression Inventory 2 (STAXI-2) Trait Anger, a measure of agitation and aggression, at Weeks 8–12 compared to previous top line data; nominal statistical significance now of p = 0.0071Improvement in Borderline Evaluation of Severity (BEST), an overall measure of BPD disease severity, at Weeks 8–12 compared to previous top line data; nominal statistical significance now of p = 0.0260Vafidemstat showed favorable results over placebo in all primary and secon

GlobeNewswire 6 months ago

ORYZF
ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

From the European Patent OfficeMADRID and CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the European Patent Office (EPO) has issued an “intention to grant” communication for Oryzon’s European patent application EP20712565.9 entitled “Methods of treating borderline personality disorder”

GlobeNewswire 7 months ago

ORYZF
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

Exploring the triple combination with venetoclax and azacitidineStudy sponsored by Oregon Health & Science University (OHSU) MADRID and CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in an investigator-initiated Phase Ib dose-finding trial of iadademstat,

GlobeNewswire 7 months ago

ORYZF

Performance Overview

Return	ORN.SG	IBEX 35... (^IBEX)
YTD	+83.58%	+12.77%
1-Year	+43.35%	+19.47%
3-Year	+7.80%	+50.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oryzon Genomics S.A. (ORN.SG)

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

High Growth Tech Stocks In Europe March 2025

European Growth Companies With High Insider Ownership To Watch

ORYZON to Provide Corporate Progress Updates at Several Events in March-April

Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat

Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board

ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

ORYZON to Provide Corporate Progress Updates at Several Events in January-February

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

Performance Overview